basic information
mesothelioma & asbestos
mesothelioma treatment
mesothelioma research

mesothelioma cancer
malignant mesothelioma
peritoneal mesothelioma
pleural mesothelioma
malignant pleural mesothelioma

picking an attorney
mesothelioma lawyers
settlement examples
asbestos litigation
abuse of lawsuits

news articles
clinical research







Mesothelioma Clinical Trials

ALIMTA (pemetrexed) Plus Gemcitabine (Gemzar) for Patients with Malignant Pleural or Peritoneal Mesothelioma who have not had previous chemotherapy

This study is currently recruiting patients.

Sponsored by

Eli Lilly and Company
For more information:National Cancer Institute (NCI)


The purposes of this study are to determine: 1) The safety of ALIMTA plus Gemcitabine and any side effects that might be associated with the combination of these two drugs. 2) Whether ALIMTA plus Gemcitabine can help patients with mesothelioma live longer. 3) Whether ALIMTA plus Gemcitabine can make the tumor smaller or disappear, and for how long. 4) To see if patients feel better while taking ALIMTA plus Gemcitabine.

Condition Treatment or Intervention
Mesothelioma  Drug: ALIMTA Plus Gemcitabine

This is a Phase II test

  • In Phase II clinical trials, the study drug or treatment is given to a larger group of people (100-300) to see if it is effective and to further evaluate its safety.  

Study Type: Interventional
Study Design: Treatment

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both


Inclusion Criteria:

  • Diagnosis of mesothelioma that can be treated with chemotherapy
  • Have received no prior chemotherapy for mesothelioma
  • Have at least one measurable lesion
  • Have an adequate performance status
  • Sign an informed consent

Exclusion Criteria:

  • Previous treatment with chemotherapy for mesothelioma
  • Treatment with an investigational drug within the last 30 days, previously completed or withdrawn from this study or any other study investigating ALIMTA
  • Treatment with radiation therapy within the last 4 weeks
  • Brain metastasis that is uncontrolled
  • Active infection or other serious condition


Privacy    Terms of Use & Copyright    Home   

Contact Us